J. Ghil

发表

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

P. Emery, J. Vencovský, A. Sylwestrzak, 2015, Annals of the rheumatic diseases.

Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

P. Emery, J. Vencovský, S. Y. Cheong, 2016, Annals of the rheumatic diseases.

Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis

J. Ghil, A. Zielinska, Younju Lee, 2019, Current medical research and opinion.

Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis

M. Genovese, P. Emery, J. Smolen, 2020, Scandinavian journal of rheumatology.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

P. Emery, J. Vencovský, A. Sylwestrzak, 2017, Rheumatology.

Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study

S. Feldman, P. Emery, G. Girolomoni, 2018, The British journal of dermatology.

Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al

P. Emery, J. Vencovský, J. Ghil, 2016, Annals of the rheumatic diseases.

Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One

J. Ghil, G. Woollett, Donghoon Shin, 2022, BioDrugs.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

P. Emery, J. Vencovský, A. Sylwestrzak, 2017, Annals of the Rheumatic Diseases.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB 4 or switching from reference etanercept to SB 4

P. Emery, J. Vencovský, A. Sylwestrzak, 2017 .

Response to: ‘Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences’ by Shah

P. Emery, J. Vencovský, J. Ghil, 2016, Annals of the Rheumatic Diseases.

Response to: ‘Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al

P. Emery, J. Vencovský, J. Ghil, 2016, Annals of the Rheumatic Diseases.

Response to: ‘Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required’ by Moots et al

P. Emery, J. Vencovský, J. Ghil, 2016, Annals of the rheumatic diseases.

A Case of Internal Jugular Vein Thrombosis after in vitro Fertilization

Seok‐Min Kang, N. Chung, J. Ghil, 2004 .

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

M. Genovese, P. Emery, M. Weinblatt, 2020, Arthritis Research & Therapy.

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

J. Ghil, Minjeong Park, G. Myung, 2019, Therapeutic advances in gastroenterology.

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

M. Weinblatt, A. Baranauskaitė, J. Ghil, 2018, Arthritis & rheumatology.

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

M. Weinblatt, J. Vencovský, J. Choe, 2017, Arthritis & rheumatology.

THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4

P. Emery, J. Vencovský, A. Sylwestrzak, 2016 .

SAT0169 Maintenance and improvement in clinical efficacy between week 12 and 24 in patients with rheumatoid arthritis treated with sb4 or reference etanercept

P. Emery, J. Vencovský, J. Ghil, 2017 .

FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)

P. Emery, J. Vencovský, A. Sylwestrzak, 2015 .

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis

M. Genovese, P. Emery, M. Weinblatt, 2020, RMD Open.

THU0184 Impact of immunogenicity on clinical efficacy and administration related reaction in tnf inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis

J. Smolen, J. Vencovský, J. Ghil, 2018, THURSDAY, 14 JUNE 2018.

Response to: ‘Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences’ by Shah

P. Emery, J. Vencovský, J. Ghil, 2016, Annals of the rheumatic diseases.